Drug Profile
Research programme: inflammatory kinase inhibitors - Cellzome
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cellzome
- Developer Cellzome; GSK
- Class Small molecules
- Mechanism of Action MTOR protein inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors; ZAP 70 protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Germany
- 21 May 2012 Cellzome has been acquired and merged into GlaxoSmithKline
- 15 Sep 2008 Cellzome and GlaxoSmithKline enter into alliance to discover, develop and market kinase-targeted therapeutics to treat inflammation worldwide